United States · Venture startup

Who invested in Okogen

2 rounds we have observed, with the one investor named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$13Mraised across 2 rounds since 2018, from 2 sources

$10MSeries A$3.3MVenture
Latest round
Venture, $3.3MDec 2024
Biggest round
$10MSeries A · Mar 2018
Investors
1
See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2018201920202021202220232024
$10MSeries A$3.3MVenture
First round
Series A, $10M
Mar 2018
Biggest round
$10M
Series A · Mar 2018
Between rounds
6.8 years
from the last two

The rounds

  1. Dec 2024
    Venture$3.3M1 returning

    Source recordedSEC filing: $2.5M sold, first sale Nov 2024

  2. Mar 2018
    Series A$10M1 new

    Reported by BenzingaSEC filing: $6.2M sold, first sale Dec 2017

Founders and team

From Okogen's own website: 2 on the team.

  • Joshua H. MoriartyCEO & Director
  • Bradford A. ConlanExecutive Chairman

Everyone who backed them

Brandon CapitalVC firm2rounds

Missing a round, or an investor who was in one? Tell us.

Quick answers about Okogen

Who invested in Okogen?

Okogen's investors include Brandon Capital.

How much has Okogen raised?

Okogen has raised $13M across 2 rounds since 2018.

When did Okogen last raise?

Okogen's most recent round was a Venture of $3.3M in Dec 2024.

What was Okogen's biggest round?

Okogen's largest round on record is $10M (Series A), in Mar 2018.

Who backed Okogen first?

Okogen's first round on record, in Mar 2018, was backed by Brandon Capital.

What stage is Okogen at?

Okogen's latest named round is a Venture, in Dec 2024.

Where is Okogen based?

Okogen is based in the United States.

Companies like Okogen

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.